The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.
Pemigatinib Approved in Japan for Unresectable, FGFR+ Biliary Tract Cancer
March 23rd 2021The Japanese Ministry of Health, Labour, and Welfare has approved pemigatinib for the treatment of patients with unresectable biliary tract cancer with a FGFR2 fusion gene, worsening following chemotherapy.
Read More
CA-125 Level Informs Surveillance Strategy for Olaparib/Bevacizumab in Ovarian Cancer
March 19th 2021CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib and bevacizumab, according to an analysis from the phase 3 PAOLA-1.
Read More
Daratumumab Plus Rd Prolongs PFS in Frail, Newly Diagnosed, Transplant-Ineligible Myeloma
March 18th 2021The addition of daratumumab to lenalidomide and dexamethasone resulted in improved progression-free survival vs Rd alone in patients with newly diagnosed multiple myeloma who were not eligible for transplant—even in frail patients.
Read More
NICE Recommends Against Olaparib for Metastatic Prostate Cancer
March 8th 2021The United Kingdom’s National Institute for Health and Care Excellence will not recommend olaparib for the treatment of patients with hormone-relapsed, metastatic prostate cancer that harbors BRCA1 or BRCA2 mutations that has progressed on abiraterone acetate or enzalutamide.
Read More
Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19
March 5th 2021Maintenance treatment with lenalidomide was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug in this patient population.
Read More
Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma
March 5th 2021The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.
Read More
Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
March 4th 2021Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.
Read More
Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer
February 26th 2021February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.
Read More
Cabozantinib/Nivolumab Approaches EU Approval for Frontline Advanced RCC
February 26th 2021The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of cabozantinib plus nivolumab for use as a frontline treatment in patients with advanced renal cell carcinoma.
Read More
Pamrevlumab May Address Unmet Need for Locally Advanced Pancreatic Cancer
February 17th 2021February 17, 2021 – Pamrevlumab, a first-in-class inhibitor of connective tissue growth factor activity, is being evaluated in combination with gemcitabine and nab-paclitaxel (Abraxane) in a phase 3 trial for patients with unresectable locally advanced pancreatic cancer, a population in need of new options.
Read More
Fedratinib Approved in Europe for Newly Diagnosed and Previously Treated Myelofibrosis
February 9th 2021February 9, 2021 - The European Commission has granted a full marketing authorization for fedratinib for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocytopenia myelofibrosis who have not received JAK inhibitors or who have received ruxolitinib.
Read More
Gilteritinib Receives Conditional Approval in China for FLT3+ AML
February 4th 2021February 4, 2021 - The China National Medical Products Administration has granted a conditional approval to gilteritinib for use in adult patients with relapsed or refractory acute myeloid leukemia with a FLT3 mutation detected by a validated test.
Read More
Larotrectinib Elicits Early Clinical Activity in NTRK Fusion–Positive Lung Cancer
February 2nd 2021February 2, 2021 — Larotrectinib was found to elicit high response rates, durable responses, and to extend survival benefit in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.
Read More
QoL, Efficacy Data Support Use of Frontline Lorlatinib as New Standard in ALK+ NSCLC
February 2nd 2021February 2, 2021 - The time to treatment deterioration for symptoms such as cough, dyspnea, and pain in the chest was found to be comparable between treatment-naïve patients with ALK-positive non–small cell lung cancer who received lorlatinib versus crizotinib.
Read More
Pembrolizumab Approaches EU Approval for Expanded Indication in Relapsed/Refractory Hodgkin Lymphoma
February 1st 2021February 1, 2020 - The European Medicines Agency’s Committee of Medicinal Products for Human Use has recommended a label expansion for pembrolizumab for use as a single agent in adult and pediatric patients aged 3 years and older with relapsed/refractory classical Hodgkin lymphoma for whom autologous stem cell transplant has failed or following at least 2 previous therapies when ASCT is not an option.
Read More
Neoadjuvant Atezolizumab Elicits Impressive Responses in Resectable NSCLC
January 30th 2021January 30, 2021 - Neoadjuvant atezolizumab followed by surgery resulted in a major pathologic response in 21% of patients with resectable stage IB-IIIB non–small cell lung cancer, as well as significant surgical outcomes with a high rate of R0 resection.
Read More